Vergoeding 2019-2023 voor ATC-subgroep A10BJ : Glucagonachtig peptide-1-agonisten (glp-1-agonisten)
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| A10BJ01 Exenatide | 730.960 | 588.730 | 478.400 | 358.640 | 43.260 |
| A10BJ02 Liraglutide (Saxenda ®) | 13.785.300 | 11.639.700 | 9.275.700 | 17.715.000 | 26.693.700 |
| A10BJ03 Lixisenatide (Lyxumia ®) | 83.417 | 65.620 | 42.772 | 35.858 | 44.530 |
| A10BJ05 Dulaglutide (Trulicity ®) | 2.640.200 | 3.587.500 | 4.413.300 | 7.322.800 | 7.076.300 |
| A10BJ06 Semaglutide (Ozempic ®) | 9.289.800 | 24.173.000 | 36.169.000 | 55.062.900 | 83.358.200 |
| Totaal | 26.529.677 | 40.054.550 | 50.379.172 | 80.495.198 | 117.215.990 |